Aerosol probes of emphysema progression in dogs treated with all trans retinoic acid--an exploratory study.
This study used aerosol probes and lung function tests to investigate whether all trans retinoic acid (RA) can reverse experimental emphysema in dogs. Three dogs were evaluated with lung mechanics tests, including inspiratory capacity (IC), total lung capacity (TLC), and the ratio of forced expired volume in 0.5 sec to forced vital capacity (FEV0.5/FVC), an aerosol-derived measure of pulmonary airspace size (effective airspace diameter, EAD), and an aerosol-derived measure of nonuniform ventilation (aerosol dispersion, AD). Emphysema was induced by exposure to aerosolized papain. At 11 or 12 weeks post-papain exposure, dogs received oral RA (2 mg/kg/day) for 8 weeks, and were followed for an additional 4 weeks after stopping RA treatment. In all dogs, lung injury increased in the first 11-12 weeks following papain exposure, as evidenced by increasing trends of inspiratory capacity IC, TLC, EAD, and AD, and a decreasing trend of FEV0.5/FVC. These parameters of lung injury partially and transiently reversed their trends between 2 and 6 weeks following the initiation of RA treatment. A sham RA-treated group was not studied. However, similar reversals of lung injury were not seen in a previous study of dogs treated with papain but not RA, suggesting that RA altered emphysema progression in the current study. The limited reversal of lung injury in this study contrasts with more pronounced treatment effects seen in previous studies with rats. This paper discusses possible reasons for differences in these studies, as well as suggestions for improved experimental investigations of emphysema therapies.
Rosenthal
Frank S
FS
School of Health Sciences, Purdue University, 500 Stadium Mall Drive, West Lafayette, IN 47907, USA. frank@purdue.edu
D000336:Aerosols; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004285:Dogs; D005541:Forced Expiratory Volume; D007320:Inspiratory Capacity; D008297:Male; D010206:Papain / Q000009:adverse effects*; D011656:Pulmonary Emphysema / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D051381:Rats; D012129:Respiratory Function Tests; D019141:Respiratory System Agents / Q000008:administration & dosage*; D014109:Total Lung Capacity; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage*; D014797:Vital Capacity
D000336:Aerosols; D000970:Antineoplastic Agents; D019141:Respiratory System Agents; D014212:Tretinoin; D010206:Papain